Recent 8-K filings for USAQ
Highest-materiality recent filing
QHSLab receives $1.4M default notice on two convertible notes; expects not to pay by Feb 27
- Received Notice of Default from Mercer Street Global Opportunity Fund for two secured promissory notes (August 2021 and July 2022).
- Lender demands $1,400,853.77 principal+18% accrued interest; company disputes amount and expects not to meet Feb 27 deadline.
-
QHSLab Q2 2026: ISP revenue up 86% to $491K; net income of $38K vs loss of $53K YoY
Total revenue $847K, up 40% YoY; gross margin expanded to 69.6% from 65.9%.
-
QHSLab presents at Planet MicroCap Las Vegas 2026; no financial details disclosed
Participating in Planet MicroCap Las Vegas 2026 conference June 16–18 at Bellagio Resort, Las Vegas.
-
Unaudited April 2026 revenue $325,889, up 57% from $207,538 in April 2025.
-
QHSLab reports 127% YoY ISP revenue growth to $370K in Q1 2026; launches GLP-1 support program
Unaudited Q1 2026 ISP revenue of $370,000, up 127% from $163,000 in Q1 2025.
-
QHSLab reports fiscal 2025 net income of $457K, revenue up 26% to $2.69M
Revenue $2.69M (+26% YoY); net income $457,417 vs net loss $259,239 in 2024.
-
QHSLab reports preliminary 2025 revenue up 25% to $2.68M, debt cut to $20k
Revenue $2,676,074, up 25% YoY; gross profit $1,795,182, up 32% YoY.
-
QHSLab repurchases $470K promissory note with 1.57M shares, extinguishing related-party debt
Repurchased and cancelled promissory note held by MedScience; outstanding principal and interest $470,529 as of Dec 31, 2025.
-
QHSLab initiates board expansion to add independent directors; convertible debt eliminated
Process to add independent board members commenced; interviews and meetings with candidates underway.
-
QHSLab reports 32% revenue growth to $1.99M, eliminates most convertible debt, cash ~$630k
Revenue $1.99M for nine months ended Sep 30, 2025 (+32% YoY); gross margin 66%.
-
QHSLab converts $126,548 of note into 421,827 shares; extends remaining $20k to Dec 2026
Converted $126,548 of principal and accrued interest into 421,827 common shares at $0.30/share.
-
QHSLab raises $500K in equity, retires $1.4M convertible debt; clean balance sheet entering 2026
Private placement of 1,666,663 shares at $0.30/share plus 416,666 warrants exercisable at $0.60 through Dec 2030.
-
QHSLab launches Q-Cog cognitive assessment; pilot finds 54% high-risk in 168 patients
Launched Q-Cog, a cloud-based digital tool for primary care screening of Mild Cognitive Impairment and dementia.
-
QHSLab furnishes December 2025 corporate presentation on Form 8-K
QHSLab, Inc. (USAQ) filed a Form 8-K on December 1, 2025, to furnish its December 2025 Corporate Presentation.
-
QHSLab nine-month revenue $1.99M; retires convertible notes, eliminates dilution overhang
Nine-month 2025 revenue $1.99M, up 32% YoY from $1.51M; gross profit $1.32M.
-
QHSLab retires $1.4M in convertible notes for $300K; Q3 revenue up 35% to $737K
Repurchased and cancelled $1.4M+ in defaulted convertible notes for $300K cash; conversion rights at $0.20/share eliminated.
-
QHSLab launches Pediatric Health Assessment with multi-location Texas pediatric group
Tool integrates behavioral screeners (PSC-17, SDQ) with allergy/asthma metrics (CARAT) and OTC medication use.
-
QHSLab (USAQ) opens first co-branded behavioral health center in Miami with QHS Healthcare
First QHS Behavioral Healthcare Center (QBHC) opened in Miami on July 8, 2025, in partnership with Global Behavioral Healthcare Group Corp.
-
QHSLab publishes two peer-reviewed studies validating digital assessment tools in primary care
Study in Journal of Psychosomatic Research: help-seeking behavior in allergic rhinitis reduces negative impact on anxiety and depression.
-
QHSLab issues May 2025 corporate presentation without specific financial updates
Presentation covers business and operations; no financial results or guidance included.
-
QHSLab in advanced debt restructuring talks with Catheter Precision to improve balance sheet
Discussions to restructure OID Notes (previously held by Mercer Street Global Opportunity Fund) held by Catheter Precision.
-
QHSLab Q1 revenue up 32% to $645K; gross margin expands to 66.6%
Total revenue $645,419 vs $488,587 in Q1 2024, a 32.1% increase.
-
QHSLab (USAQ) hires Hayden IR to boost investor visibility
QHSLab engaged Hayden IR, a national investor relations firm, to raise visibility and strengthen relationships.
-
QHSLab receives $1.4M default notice on two convertible notes; expects not to pay by Feb 27
Received Notice of Default from Mercer Street Global Opportunity Fund for two secured promissory notes (August 2021 and July 2022).
-
QHSLab reports 98% Q4 revenue surge, first profitable year with net income of $69,188
Q4 revenue $625,981 (+98% YoY); net income $40,838 vs loss $86,627 Q4 2023.
-
QHSLab announces co-marketing partnership with Town Total Compounding covering 200+ practices
Partnership will introduce QHSLab's Integrated Service Program to over 200 primary care practices in Town Total's network.
-
QHSLab furnishes January 2025 Corporate Presentation without specific content
Corporate presentation filed as Exhibit 99.1, made available on January 21, 2025.
-
QHSLab to exhibit at Pri-Med South conference Feb 2025, targeting 5,000 primary care professionals
Company will exhibit at Pri-Med South in Fort Lauderdale, Feb 6-8, 2025.
-
QHSLab projects $10M revenue with 250-300 physicians at >65% gross margins
Single provider using full suite can generate $30-50k annual revenue for QHSLab.
-
QHSLab and SDSU receive NSF invitation to submit STTR application for AIR-GUIDDE technology
NSF invites QHSLab and South Dakota State University to submit full Phase I STTR application for AIR-GUIDDE drug delivery platform.
-
QHSLab reports Oct sales up 110% to $225k; APA abstracts accepted for 2025
October 2024 unaudited sales ~$225,000, a 110% increase YoY; annualized run rate $2.7M.
-
QHSLab Q3 revenue up 62% to $544K, net income $49.8K, gross margin 67.1%
Revenue $544,285 (+62% YoY); gross margin 67.1% (up from 56.3%). Net income $49,765 vs ($82,000) loss in Q3 2023.
-
QHSLab adds psychiatry advisor Dr. Juan Oms; grants 100k shares in compensation
Dr. Oms will provide strategic advisory services in psychiatry and behavioral health under a 24-month consulting agreement.
-
QHSLab reports 40% revenue growth, positive cash flow, and strategic review
Revenue increased 40% year-over-year to over $1.5 million in the third quarter of 2024.
-
QHSLab secures $297K grant from global consumer health firm for allergic rhinitis digital study
QHSLab received $297,360 grant from a Global Leader in Consumer Health to advance digital medicine for allergic rhinitis.
-
QHSLab doubles assessment completions to ~50K year-to-date; two abstracts accepted at ACAAI
Platform processed ~50,000 assessments in 2024 YTD, more than double the same period in 2023.
-
QHSLab reports strong Q2 2024: revenue +17%, gross margin 62.2%, net loss down 97% to $2.9K
Q2 revenue $473,073 (+17% YoY); six-month revenue $961,660 (+27%).
-
QHSLab dismisses auditor Accell, engages Astra; prior reports included going concern uncertainty
Dismissed Accell Audit & Compliance as independent auditor effective June 4, 2024.
-
Q1 2024 revenue $488,587 (+38.6% YoY); Integrated Service Program revenue surged 268% to $127,004.
-
QHSLab appoints Dr. Marcos Sanchez-Gonzalez as VP of Medical and Scientific Affairs
Dr. Marcos Sanchez-Gonzalez appointed VP of Medical and Scientific Affairs effective May 2, 2024.
-
QHSLab reports preliminary Q1 revenue $488,587, up 38% YoY; gross profit $286,157, up 53%
Revenue of $488,587, up 38% from $352,799 in Q1 2023.
-
QHSLab furnishes corporate presentation; no specific financial data in filing
Company furnished a corporate presentation for meetings with broker-dealers and investors.
-
QHSLab 2023 revenue up 13% to $1.41M; net loss halved to $(240K)
Revenue of $1,408,995, up from $1,243,186 in 2022, driven by allergy kits and digital medicine subscriptions.
-
QHSLab integrates digital medicine assessments with athenahealth EHR, targeting 160,000 providers
Integration with athenaHealth EMR gives QHSLab access to over 160,000 medical professionals.
-
QHSLab gains 6 new ISP customers; expects quarterly ISP revenue surge >100%
Six new multi-location customer accounts added in Q4 2023, covering 16 primary care facilities in South Florida.
-
QHSLab reports 30K+ digital assessments YTD, over $1M revenue for 9 months
Over 30,000 patient digital medicine assessments in first 9 months of 2023; 800 initiated allergen immunotherapy.
-
QHSLab reduces note conversion price to $0.025 on $10,500; in default on $806K and $440K notes
On Oct 5, 2023, QHSLab reduced conversion price on $10,500 of $806K Note to $0.025 per share at holder's request.
-
QHSLab Q1 2023 revenue $352,799, up 32% sequentially; gross margin 53.1%
Net operating loss narrowed 17.1% to $120,758 from $145,701 in Q4 2022.
-
QHSLab enters representation agreement with Healthcare IT Specialists for digital health platform
Representation agreement with Healthcare Information Technology Specialists, LLC to recruit physician clients for QHSLab's digital health platform.
-
QHSLab reiterates $7.5B addressable market for ISP digital health; expects $40-75K per practice
Reiterates 2022 projection of $7.5B addressable market for Integrated Service Program (ISP) digital health solution.
-
QHSLab projects $7.5B addressable market for ISP digital health solution for primary care
Company projects $7.5B addressable market for Integrated Service Program (ISP) targeting ~250,000 independent primary care providers.
Earnings & guidance
Materiality & sentiment trend
Max materiality 0.85 · Median 0.62 · Most common event other_material